A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO)
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2014
At a glance
- Drugs Eflornithine (Primary) ; Sulindac (Primary)
- Indications Cancer; Pain; Rheumatic disorders
- Focus Biomarker; Pharmacodynamics
- 30 May 2013 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 30 May 2013 Planned initiation date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 17 Jul 2012 New trial record